Current Studies Open to Enrollment

Current Studies Open to Enrollment

Current Studies

We are currently enrolling patients into the studies listed below. Patients need to meet the criteria for study enrollment before entry into these clinical trials. Please contact us if you would like to consider participating in one of these studies.

Seizures

King Pharmaceuticals – K826-05-3001

Vanquix

A Phase 3, Randomized, Double-Blind, Parallel, Placebo-Controlled, Multicenter Study, with Optional Open-Label Continuation, of the efficacy and Safety of Vanquix ™ Auto-Injector (Diazepam Injection) for the Management of Selected, Refractory, Patients with Epilepsy who Require Intermittent Medical Intervention to Control Episodes of Acute Repetitive Seizures

Pfizer Pharmaceuticals – A0081074

Lyrica (peds)

A Placebo-Controlled, Escalating Dose, Multiple Dose Study to Evaluate the Safety, Tolerability and Phamacokinetics of Pregabalin in Pediatric Patients with Partial Onset Seizures

Schwarz - SP902

Lacosamide

A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/day Mono-therapy in Subjects with Partial-onset Seizures

Migraine

NINDS/Emmes Corporation - CMTT

Chronic Migraine Treatment Trial (CMTT)

The Chronic Migraine Treatment Trial (CMTT) is a streamlined, double-blind, placebo-controlled randomized clinical trial expected to randomize 250 participants with chronic migraine across at least 50 sites to either treatment with topiramate (up to 100 mg/day) and propranolol (up to 240 mg/day LA formulation) or treatment with topiramate (up to 100 mg/day) and placebo. Randomized participants will be followed for six months with the primary objective to assess the efficacy and safety of propranolol in combination with topiramate for reducing the number of days with severe headache (at least moderate in severity, lasting at least 4 hours during a 28-day interval) following six months of treatment.

Stroke

CoAxia – MA 0027

SENTIS

Safety and Efficacy of Neuro-Flo Technology in Ischemic Stroke

Cordis - HUD

ENTERPRISE

Vascular Reconstruction Device and Delivery System (A Humanitarian Use Device)

Concentric Medical – INT-REG-001

MERCI REGISTRY

Prospective, Open-Label, Competitive Enrollment, Multi-center, Multi-National Registry

Cordis – P06-3603

SAPPHIRE

Stenting And Angioplasty With Protection In Patients At High-Risk For Endarterectomy

Penumbra – CLP1953.A

Penumbra Imaging Collaborative Study (PICS)

A Multicenter Trial to Assess Outcone of Patients Revascularized by the Penumbra™ System

NINDS

Interventional Management of Stroke Study III (IMS III)

A Phase III, Randomized, Multi-Center, Open Label, 900 Subject Clinical Trial That Will Examine Whether a Combined Intravenous (IV) and Intra-arterial (IA) Approach to Recanalization is Superior to Standard IV rt-PA (Activase) Alone When Initiated Within Three Hours of Acute Ischemic Stroke Onset.

Multiple Sclerosis

Investigator Initiated Study - (with support from Bayer Healthcare)

Neuropsychological Assessments in the Multiple Sclerosis Clinic